BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Monti JM, Leopoldo M, Jantos H. Systemic administration and local microinjection into the central nervous system of the 5-HT(7) receptor agonist LP-211 modify the sleep-wake cycle in the rat. Behav Brain Res 2014;259:321-9. [PMID: 24286819 DOI: 10.1016/j.bbr.2013.11.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Samarajeewa A, Goldemann L, Vasefi MS, Ahmed N, Gondora N, Khanderia C, Mielke JG, Beazely MA. 5-HT7 receptor activation promotes an increase in TrkB receptor expression and phosphorylation. Front Behav Neurosci 2014;8:391. [PMID: 25426041 DOI: 10.3389/fnbeh.2014.00391] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
2 Zou Y, Wang W, Jin H, Nie X, Xu J, Liu Y, Kang J. The influence of 5-HT1A receptors in the dorsal raphé nucleus on genioglossus activity. Respir Physiol Neurobiol 2018;249:11-5. [PMID: 29208535 DOI: 10.1016/j.resp.2017.11.009] [Reference Citation Analysis]
3 Kim Y, Kim H, Lee J, Lee JK, Min SJ, Seong J, Rhim H, Tae J, Lee HJ, Choo H. Discovery of β-Arrestin Biased Ligands of 5-HT7R. J Med Chem 2018;61:7218-33. [PMID: 30028132 DOI: 10.1021/acs.jmedchem.8b00642] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Blattner KM, Canney DJ, Pippin DA, Blass BE. Pharmacology and Therapeutic Potential of the 5-HT7 Receptor. ACS Chem Neurosci 2019;10:89-119. [PMID: 30020772 DOI: 10.1021/acschemneuro.8b00283] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
5 Quintero-Villegas A, Valdés-Ferrer SI. Central nervous system effects of 5-HT7 receptors: a potential target for neurodegenerative diseases. Mol Med 2022;28:70. [PMID: 35725396 DOI: 10.1186/s10020-022-00497-2] [Reference Citation Analysis]
6 Lynch JJ 3rd, Van Vleet TR, Mittelstadt SW, Blomme EAG. Potential functional and pathological side effects related to off-target pharmacological activity. J Pharmacol Toxicol Methods 2017;87:108-26. [PMID: 28216264 DOI: 10.1016/j.vascn.2017.02.020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
7 Volpicelli F, Speranza L, di Porzio U, Crispino M, Perrone-Capano C. The serotonin receptor 7 and the structural plasticity of brain circuits. Front Behav Neurosci 2014;8:318. [PMID: 25309369 DOI: 10.3389/fnbeh.2014.00318] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
8 Ciranna L, Catania MV. 5-HT7 receptors as modulators of neuronal excitability, synaptic transmission and plasticity: physiological role and possible implications in autism spectrum disorders. Front Cell Neurosci 2014;8:250. [PMID: 25221471 DOI: 10.3389/fncel.2014.00250] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
9 Deau E, Robin E, Voinea R, Percina N, Satała G, Finaru A, Chartier A, Tamagnan G, Alagille D, Bojarski AJ, Morisset-lopez S, Suzenet F, Guillaumet G. Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT 7 )/5-Hydroxytryptamine 2A (5-HT 2A ) Receptor Antagonists and Evaluation by [ 18 F]-PET Imaging in a Primate Brain. J Med Chem 2015;58:8066-96. [DOI: 10.1021/acs.jmedchem.5b00874] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
10 Thirumaran S, Lepailleur A, Rochais C. Structure-activity relationships of serotonin 5-HT7 receptors ligands: A review. European Journal of Medicinal Chemistry 2019;183:111705. [DOI: 10.1016/j.ejmech.2019.111705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Volpicelli F, Speranza L, Pulcrano S, De Gregorio R, Crispino M, De Sanctis C, Leopoldo M, Lacivita E, di Porzio U, Bellenchi GC, Perrone-Capano C. The microRNA-29a Modulates Serotonin 5-HT7 Receptor Expression and Its Effects on Hippocampal Neuronal Morphology. Mol Neurobiol 2019;56:8617-27. [PMID: 31292861 DOI: 10.1007/s12035-019-01690-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
12 Leiser SC, Iglesias-Bregna D, Westrich L, Pehrson AL, Sanchez C. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. J Psychopharmacol 2015;29:1092-105. [PMID: 26174134 DOI: 10.1177/0269881115592347] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
13 Nikiforuk A. Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date. CNS Drugs 2015;29:265-75. [PMID: 25721336 DOI: 10.1007/s40263-015-0236-0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
14 Shelton J, Yun S, Losee Olson S, Turek F, Bonaventure P, Dvorak C, Lovenberg T, Dugovic C. Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci 2014;8:453. [PMID: 25642174 DOI: 10.3389/fnbeh.2014.00453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
15 Costa L, Sardone LM, Lacivita E, Leopoldo M, Ciranna L. Novel agonists for serotonin 5-HT7 receptors reverse metabotropic glutamate receptor-mediated long-term depression in the hippocampus of wild-type and Fmr1 KO mice, a model of Fragile X Syndrome. Front Behav Neurosci 2015;9:65. [PMID: 25814945 DOI: 10.3389/fnbeh.2015.00065] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
16 Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SCR, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H, Roberts A, Roth BL, Roumier A, Sanger GJ, Teitler M, Sharp T, Villalón CM, Vogel H, Watts SW, Hoyer D. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol Rev 2021;73:310-520. [PMID: 33370241 DOI: 10.1124/pr.118.015552] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]